Compare LEDS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | LPCN |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 18.7M |
| IPO Year | 2010 | 2011 |
| Metric | LEDS | LPCN |
|---|---|---|
| Price | $2.02 | $1.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 8.1K | ★ 1.6M |
| Earning Date | 11-27-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $43,009,000.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.02 |
| P/E Ratio | $107.50 | ★ N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.01 | $1.40 |
| 52 Week High | $3.62 | $12.37 |
| Indicator | LEDS | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 30.05 |
| Support Level | $1.85 | N/A |
| Resistance Level | $2.45 | $2.50 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 50.00 | 9.12 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.